Related Experiment Video
Updated: Jun 24, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Advances in the pharmacological management of breathlessness
David C Currow1, Alicia M Ward, Amy P Abernethy
1Flinders University, Daw Park, SA, Australia. david.currow@health.sa.gov.au
Purpose Of Review:
To explore advances in the pharmacological treatment of refractory breathlessness and the physiological evidence for treatments.
Recent Findings:
The evidence for the role of oral and parenteral opioids in the reduction of breathlessness continues to strengthen from individual studies and from systematic reviews. Importantly, more data are emerging about a lack of lowering in oxygenation or carbon dioxide retention with opioid therapy. In healthy volunteers and those with refractory dyspnoea, nebulized frusemide appears to be worthy of further investigation with adequately powered phase III studies.
Summary:
Opioids prescribed regularly can help to predictably and safely reduce breathlessness for people with a range of end-stage illnesses.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
